Evidence map›Paper›PMID 41322132›Full record

ArticleMaterials today. Bio2025

Radio-magnetic dual-functional microspheres for magnetic hyperthermia therapy combined with radioembolization of hepatocellular carcinoma.

Manran Wu, Dong Wang, Yu Qin, Xunhao Qi, Qian Huang, Xingwei Sun, Yong Jin, Ran Zhu, Guanglin Wang, Pengfei Rong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Manran WuDepartment of Radiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Dong WangState Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, 215123, China.
Yu QinState Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, 215123, China.
Xunhao QiState Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, 215123, China.
Qian HuangState Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, 215123, China.
Xingwei SunDepartment of Intervention, The Second Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Yong JinDepartment of Intervention, The Second Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Ran ZhuState Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, 215123, China.
Guanglin WangState Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, 215123, China.
Pengfei RongDepartment of Radiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) remains a formidable clinical challenge due to its aggressive nature, high recurrence rate, and limited therapeutic options, particularly for intermediate-advanced stage patients who are ineligible for surgical resection. Current transarterial chemoembolization (TACE) and conventional transarterial radioembolization (TARE) often face challenges such as incomplete tumor necrosis and radioresistance. To address these critical clinical issues, we develop an innovative polydopamine-coated

Indexed as

Hepatocellular carcinomaMagnetic hyperthermia therapyRadio-magnetic microspheresSPECT imagingTransarterial radioembolization

Identifiers

PMID41322132
PMCPMC12664441

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.